December 10th 2024
Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).
December 4th 2024
Watch the series now!
Top 5 Content From Institute for Value-Based Medicine® Events in 2023
ICYMI: Highlights From the 2023 Community Oncology Conference
Research Reveals the Role of Structural Racism in Lung Cancer Risk
Overcoming Challenges to Value-Based Care Implementation: Grant Andres
Dr Kathi Mooney Previews Oncology Hospital at Home Presentation